Development of an effective delivery system for intranasal immunization against Mycobacterium tuberculosis ESAT-6 antigen

References

• Amidi M, Mastrobattista E, Jiskoot W, Hennink WE. 2010. Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev. 62:59–82.
   PubMed Web of Science ®Google Scholar
• Andersen P. 2001. TB vaccines: progress and problems. Trends Immunol. 22:160–168.
   PubMed Web of Science ®Google Scholar
• Armstrong J, Hart PA. 1975. Phagosome-lysosome interactions in cultured macrophages infected with virulent tubercle bacilli. Reversal of the usual nonfusion pattern and observations on bacterial survival. J Exp Med. 142:1–16.
   PubMed Web of Science ®Google Scholar
• Babiuk LA. 1999. Broadening the approaches to developing more effective vaccines. Vaccine. 17:1587–1595.
   PubMed Web of Science ®Google Scholar
• Balu S, Reljic R, Lewis MJ, Pleass RJ, McIntosh R, van Kooten C, et al. 2011. A novel human IgA monoclonal antibody protects against tuberculosis. J Immunol. 186:3113–3119.
   PubMed Web of Science ®Google Scholar
• Black M, Trent A, Tirrell M, Olive C. 2010. Advances in the design and delivery of peptide subunit vaccines with a focus on Toll-like receptor agonists. Expert Rev Vaccine. 9:157–173.
   PubMed Web of Science ®Google Scholar
• Brandt L, Elhay M, Rosenkrands I, Lindblad EB, Andersen P. 2000. ESAT-6 Subunit Vaccination against Mycobacterium tuberculosis. Infect Immunity. 68:791–795.
   PubMed Web of Science ®Google Scholar
• Brown F. 1992. Peptide vaccines: fantasy or reality? World J Microbiol Biotechnol. 8:52–53.
   PubMed Web of Science ®Google Scholar
• Carpenter ZK, Williamson ED, Eyles JE. 2005. Mucosal delivery of microparticle encapsulated ESAT-6 induces robust cell-mediated responses in the lung milieu. J Control Release. 104:67–77.
   PubMed Web of Science ®Google Scholar
• Encinales L, Zuñiga J, Granados-Montiel J, Yunis M, Granados J, Almeciga I, et al. 2010. Humoral immunity in tuberculin skin test anergy and its role in high-risk persons exposed to active tuberculosis. Mol Immunol. 47:1066–1073.
   PubMed Web of Science ®Google Scholar
• Fine PE. 1995. Variation in protection by BCG: implications of and for heterologous immunity. Lancet. 346:1339–1345.
   PubMed Web of Science ®Google Scholar
• Gelperina S, Kisich K, Iseman MD, Heifets L. 2005. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med. 172:1487–1490.
   PubMed Web of Science ®Google Scholar
• Ghendon Y, Markushin S, Vasiliev Y, Akopova I, Koptiaeva I, Krivtsov G, et al. 2009. Evaluation of properties of chitosan as an adjuvant for inactivated influenza vaccines administered parenterally. J Med Virol. 81:494–506.
   PubMed Web of Science ®Google Scholar
• Gutierro I, Hernandez R, Igartua M, Gascon A, Pedraz J. 2002. Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine. 21:67–77.
   PubMed Web of Science ®Google Scholar
• Harboe M, Oettinger T, Wiker HG, Rosenkrands I, Andersen P. 1996. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect Immun. 64:16–22.
   PubMed Web of Science ®Google Scholar
• Henson D, van Dissel J, Joosten S, Graves A, Hoff S, Soonawala D, et al. 2014. Vaccination with a Hybrid 1 (H1) fusion protein combined with a liposomal adjuvant (CAF01) induced antigen specific T-cells 3 years post vaccination in a human clinical trial.(VAC7P. 971). J Immunol. 192:141. 16–116.
   Web of Science ®Google Scholar
• Huang M, Khor E, Lim L-Y. 2004. Uptake and cytotoxicity of chitosan molecules and nanoparticles: effects of molecular weight and degree of deacetylation. Pharm Res. 21:344–353.
   PubMed Web of Science ®Google Scholar
• Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher A, Davis S. 2001. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev. 51:81–96.
   PubMed Web of Science ®Google Scholar
• Jabbal-Gill I. 2010. Nasal vaccine innovation. J Drug Target. 18:771–786.
   PubMed Web of Science ®Google Scholar
• Joshi VB, Geary SM, Salem AK. 2013. Biodegradable particles as vaccine antigen delivery systems for stimulating cellular immune responses. Hum Vaccines Immunotherapeut. 9:2584–2590.
   PubMed Web of Science ®Google Scholar
• Kochi A. 1994. Tuberculosis: distribution, risk factors, mortality. Immunobiology. 191:325–336.
   PubMed Web of Science ®Google Scholar
• Levine MM, Sztein MB. 2004. Vaccine development strategies for improving immunization: the role of modern immunology. Nat Immunol. 5:460–464.
   PubMed Web of Science ®Google Scholar
• Li G, Liu Z, Liao B, Zhong N. 2009. Induction of Th1-type immune response by chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen Der p 2 for oral vaccination in mice. Cell Mol Immunol. 6:45–50.
   PubMed Web of Science ®Google Scholar
• Mahairas GG, Sabo PJ, Hickey MJ, Singh DC, Stover CK. 1996. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol. 178:1274–1282.
   PubMed Web of Science ®Google Scholar
• McNeela EA, Jabbal-Gill I, Illum L, Pizza M, Rappuoli R, Podda A, et al. 2004. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine. 22:909–914.
   PubMed Web of Science ®Google Scholar
• Nagamoto T, Hattori Y, Takayama K, Maitani Y. 2004. Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery. Pharm Res. 21:671–674.
   PubMed Web of Science ®Google Scholar
• Porporatto C, Bianco ID, Correa SG. 2005. Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration. J Leukoc Biol. 78:62–69.
   PubMed Web of Science ®Google Scholar
• Rauw F, Gardin Y, Palya V, Anbari S, Gonze M, Lemaire S, et al. 2010. The positive adjuvant effect of chitosan on antigen-specific cell-mediated immunity after chickens vaccination with live Newcastle disease vaccine. Vet Immunol Immunopathol. 134:249–258.
   PubMed Web of Science ®Google Scholar
• Ravn P, Demissie A, Eguale T, Wondwosson H, Lein D, Amoudy HA, et al. 1999. Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J Infect Dis Infectious. 179:637–645.
   PubMed Web of Science ®Google Scholar
• Reddy ST, Swartz MA, Hubbell JA. 2006. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol. 27:573–579.
   PubMed Web of Science ®Google Scholar
• Shaji J, Jain V, Lodha S. 2010. Chitosan: a novel pharmaceutical excipient. Int J Pharm Appl Sci. 1:11–28.
   Google Scholar
• Skeiky YAW, Sadoff JC. 2006. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol. 4:469–476.
   PubMed Web of Science ®Google Scholar
• Slütter B, Bal S, Keijzer C, Mallants R, Hagenaars N, Que I, et al. 2010. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. Vaccine. 28:6282–6291.
   PubMed Web of Science ®Google Scholar
• Slütter B, Plapied L, Fievez V, Alonso Sande M, des Rieux A, Schneider Y-J, et al. 2009. Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. J Control Release. 138:113–121.
   PubMed Web of Science ®Google Scholar
• Soleimanpour S, Farsiani H, Mosavat A, Ghazvini K, Eydgahi MRA, Sankian M, et al. 2015. APC targeting enhances immunogenicity of a novel multistage Fc-fusion tuberculosis vaccine in mice. Appl Microbiol Biotechnol. 99:10467–10480.
   PubMed Web of Science ®Google Scholar
• Strong P, Clark H, Reid K. 2002. Intranasal application of chitin microparticles down-regulates symptoms of allergic hypersensitivity to dermatophagoides pteronyssinus and Aspergillus fumigatus in murine models of allergy. Clin Exp Allergy. 32:1794–1800.
   PubMed Web of Science ®Google Scholar
• Tebianian M, Hoseini AZ, Ebrahimi SM, Memarnejadian A, Mokarram AR, Mahdavi M, et al. 2011. Cloning, expression, and immunogenicity of novel fusion protein of Mycobacterium tuberculosis based on ESAT-6 and truncated C-terminal fragment of HSP70. Biologicals. 39:143–148.
   PubMed Web of Science ®Google Scholar
• Vila A, Sánchez A, Janes K, Behrens I, Kissel T, Jato JLV, et al. 2004. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur J Pharm Biopharm. 57:123–131.
   PubMed Web of Science ®Google Scholar
• Wang L, Shi C, Fan X, Xue Y, Bai Y, Xu Z. 2007. Expression and immunogenicity of recombinant Mycobacterium bovis Bacillus Calmette-Guérin strains secreting the antigen ESAT-6 from Mycobacterium tuberculosis in mice. Chinese Med J. 120:1220–1225.
   PubMed Web of Science ®Google Scholar
• Young DB, Stewart GR. 2002. Tuberculosis vaccines. Br Med Bull. 62:73–86.
   PubMed Web of Science ®Google Scholar
• Zuñiga J, Torres-García D, Santos-Mendoza T, Rodriguez-Reyna TS, Granados J, Yunis EJ. 2012. Cellular and humoral mechanisms involved in the control of tuberculosis. Clinical Develop Immunol. 2012:193923. doi: 10.1155/2012/193923.
   PubMedGoogle Scholar